The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hepatocyte Growth Factor Market Research Report 2024
Synopsis
Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration, and in wound healing.
The global Hepatocyte Growth Factor market was valued at US$ 45 million in 2023 and is anticipated to reach US$ 287.9 million by 2030, witnessing a CAGR of 30.0% during the forecast period 2024-2030.
Asia Pacific will be the largest region of Hepatocyte Growth Factor, which will occupy about 60% market share in 2030. North America will be the second largest market with the consumption market share of 25% in 2030. ViroMed, AnGes MG, M3 Biotechnology, AVEO Pharmaceuticals, Molecular Partners and Yooyoung Pharm are the major manufacturers of industry.
This report aims to provide a comprehensive presentation of the global market for Hepatocyte Growth Factor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatocyte Growth Factor.
Report Scope
The Hepatocyte Growth Factor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hepatocyte Growth Factor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatocyte Growth Factor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
ViroMed
AnGes MG
M3 Biotechnology
AVEO Pharmaceuticals
Molecular Partners
Yooyoung Pharm
F-star
Galaxy Biotech
Kringle Pharma
Segment by Type
Phase III (Ongoing)
Phase II (Approved)
Phase II (Ongoing)
Phase 1
Preclinical
Segment by Application
Oncology
Cardiovascular
Central Nervous System
Hematological Disorders
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hepatocyte Growth Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hepatocyte Growth Factor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration, and in wound healing.
The global Hepatocyte Growth Factor market was valued at US$ 45 million in 2023 and is anticipated to reach US$ 287.9 million by 2030, witnessing a CAGR of 30.0% during the forecast period 2024-2030.
Asia Pacific will be the largest region of Hepatocyte Growth Factor, which will occupy about 60% market share in 2030. North America will be the second largest market with the consumption market share of 25% in 2030. ViroMed, AnGes MG, M3 Biotechnology, AVEO Pharmaceuticals, Molecular Partners and Yooyoung Pharm are the major manufacturers of industry.
This report aims to provide a comprehensive presentation of the global market for Hepatocyte Growth Factor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatocyte Growth Factor.
Report Scope
The Hepatocyte Growth Factor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hepatocyte Growth Factor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatocyte Growth Factor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
ViroMed
AnGes MG
M3 Biotechnology
AVEO Pharmaceuticals
Molecular Partners
Yooyoung Pharm
F-star
Galaxy Biotech
Kringle Pharma
Segment by Type
Phase III (Ongoing)
Phase II (Approved)
Phase II (Ongoing)
Phase 1
Preclinical
Segment by Application
Oncology
Cardiovascular
Central Nervous System
Hematological Disorders
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hepatocyte Growth Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hepatocyte Growth Factor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Hepatocyte Growth Factor Market Overview
1.1 Product Overview and Scope of Hepatocyte Growth Factor
1.2 Hepatocyte Growth Factor Segment by Type
1.2.1 Global Hepatocyte Growth Factor Market Value Comparison by Type (2024-2030)
1.2.2 Phase III (Ongoing)
1.2.3 Phase II (Approved)
1.2.4 Phase II (Ongoing)
1.2.5 Phase 1
1.2.6 Preclinical
1.3 Hepatocyte Growth Factor Segment by Application
1.3.1 Global Hepatocyte Growth Factor Market Value by Application: (2024-2030)
1.3.2 Oncology
1.3.3 Cardiovascular
1.3.4 Central Nervous System
1.3.5 Hematological Disorders
1.3.6 Others
1.4 Global Hepatocyte Growth Factor Market Size Estimates and Forecasts
1.4.1 Global Hepatocyte Growth Factor Revenue 2019-2030
1.4.2 Global Hepatocyte Growth Factor Sales 2019-2030
1.4.3 Global Hepatocyte Growth Factor Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Hepatocyte Growth Factor Market Competition by Manufacturers
2.1 Global Hepatocyte Growth Factor Sales Market Share by Manufacturers (2019-2024)
2.2 Global Hepatocyte Growth Factor Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Hepatocyte Growth Factor Average Price by Manufacturers (2019-2024)
2.4 Global Hepatocyte Growth Factor Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hepatocyte Growth Factor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hepatocyte Growth Factor, Product Type & Application
2.7 Hepatocyte Growth Factor Market Competitive Situation and Trends
2.7.1 Hepatocyte Growth Factor Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Hepatocyte Growth Factor Players Market Share by Revenue
2.7.3 Global Hepatocyte Growth Factor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hepatocyte Growth Factor Retrospective Market Scenario by Region
3.1 Global Hepatocyte Growth Factor Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Hepatocyte Growth Factor Global Hepatocyte Growth Factor Sales by Region: 2019-2030
3.2.1 Global Hepatocyte Growth Factor Sales by Region: 2019-2024
3.2.2 Global Hepatocyte Growth Factor Sales by Region: 2025-2030
3.3 Global Hepatocyte Growth Factor Global Hepatocyte Growth Factor Revenue by Region: 2019-2030
3.3.1 Global Hepatocyte Growth Factor Revenue by Region: 2019-2024
3.3.2 Global Hepatocyte Growth Factor Revenue by Region: 2025-2030
3.4 North America Hepatocyte Growth Factor Market Facts & Figures by Country
3.4.1 North America Hepatocyte Growth Factor Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Hepatocyte Growth Factor Sales by Country (2019-2030)
3.4.3 North America Hepatocyte Growth Factor Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hepatocyte Growth Factor Market Facts & Figures by Country
3.5.1 Europe Hepatocyte Growth Factor Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Hepatocyte Growth Factor Sales by Country (2019-2030)
3.5.3 Europe Hepatocyte Growth Factor Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hepatocyte Growth Factor Market Facts & Figures by Country
3.6.1 Asia Pacific Hepatocyte Growth Factor Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Hepatocyte Growth Factor Sales by Country (2019-2030)
3.6.3 Asia Pacific Hepatocyte Growth Factor Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hepatocyte Growth Factor Market Facts & Figures by Country
3.7.1 Latin America Hepatocyte Growth Factor Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Hepatocyte Growth Factor Sales by Country (2019-2030)
3.7.3 Latin America Hepatocyte Growth Factor Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hepatocyte Growth Factor Market Facts & Figures by Country
3.8.1 Middle East and Africa Hepatocyte Growth Factor Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Hepatocyte Growth Factor Sales by Country (2019-2030)
3.8.3 Middle East and Africa Hepatocyte Growth Factor Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Hepatocyte Growth Factor Sales by Type (2019-2030)
4.1.1 Global Hepatocyte Growth Factor Sales by Type (2019-2024)
4.1.2 Global Hepatocyte Growth Factor Sales by Type (2025-2030)
4.1.3 Global Hepatocyte Growth Factor Sales Market Share by Type (2019-2030)
4.2 Global Hepatocyte Growth Factor Revenue by Type (2019-2030)
4.2.1 Global Hepatocyte Growth Factor Revenue by Type (2019-2024)
4.2.2 Global Hepatocyte Growth Factor Revenue by Type (2025-2030)
4.2.3 Global Hepatocyte Growth Factor Revenue Market Share by Type (2019-2030)
4.3 Global Hepatocyte Growth Factor Price by Type (2019-2030)
5 Segment by Application
5.1 Global Hepatocyte Growth Factor Sales by Application (2019-2030)
5.1.1 Global Hepatocyte Growth Factor Sales by Application (2019-2024)
5.1.2 Global Hepatocyte Growth Factor Sales by Application (2025-2030)
5.1.3 Global Hepatocyte Growth Factor Sales Market Share by Application (2019-2030)
5.2 Global Hepatocyte Growth Factor Revenue by Application (2019-2030)
5.2.1 Global Hepatocyte Growth Factor Revenue by Application (2019-2024)
5.2.2 Global Hepatocyte Growth Factor Revenue by Application (2025-2030)
5.2.3 Global Hepatocyte Growth Factor Revenue Market Share by Application (2019-2030)
5.3 Global Hepatocyte Growth Factor Price by Application (2019-2030)
6 Key Companies Profiled
6.1 ViroMed
6.1.1 ViroMed Corporation Information
6.1.2 ViroMed Description and Business Overview
6.1.3 ViroMed Hepatocyte Growth Factor Sales, Revenue and Gross Margin (2019-2024)
6.1.4 ViroMed Hepatocyte Growth Factor Product Portfolio
6.1.5 ViroMed Recent Developments/Updates
6.2 AnGes MG
6.2.1 AnGes MG Corporation Information
6.2.2 AnGes MG Description and Business Overview
6.2.3 AnGes MG Hepatocyte Growth Factor Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AnGes MG Hepatocyte Growth Factor Product Portfolio
6.2.5 AnGes MG Recent Developments/Updates
6.3 M3 Biotechnology
6.3.1 M3 Biotechnology Corporation Information
6.3.2 M3 Biotechnology Description and Business Overview
6.3.3 M3 Biotechnology Hepatocyte Growth Factor Sales, Revenue and Gross Margin (2019-2024)
6.3.4 M3 Biotechnology Hepatocyte Growth Factor Product Portfolio
6.3.5 M3 Biotechnology Recent Developments/Updates
6.4 AVEO Pharmaceuticals
6.4.1 AVEO Pharmaceuticals Corporation Information
6.4.2 AVEO Pharmaceuticals Description and Business Overview
6.4.3 AVEO Pharmaceuticals Hepatocyte Growth Factor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 AVEO Pharmaceuticals Hepatocyte Growth Factor Product Portfolio
6.4.5 AVEO Pharmaceuticals Recent Developments/Updates
6.5 Molecular Partners
6.5.1 Molecular Partners Corporation Information
6.5.2 Molecular Partners Description and Business Overview
6.5.3 Molecular Partners Hepatocyte Growth Factor Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Molecular Partners Hepatocyte Growth Factor Product Portfolio
6.5.5 Molecular Partners Recent Developments/Updates
6.6 Yooyoung Pharm
6.6.1 Yooyoung Pharm Corporation Information
6.6.2 Yooyoung Pharm Description and Business Overview
6.6.3 Yooyoung Pharm Hepatocyte Growth Factor Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Yooyoung Pharm Hepatocyte Growth Factor Product Portfolio
6.6.5 Yooyoung Pharm Recent Developments/Updates
6.7 F-star
6.6.1 F-star Corporation Information
6.6.2 F-star Description and Business Overview
6.6.3 F-star Hepatocyte Growth Factor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 F-star Hepatocyte Growth Factor Product Portfolio
6.7.5 F-star Recent Developments/Updates
6.8 Galaxy Biotech
6.8.1 Galaxy Biotech Corporation Information
6.8.2 Galaxy Biotech Description and Business Overview
6.8.3 Galaxy Biotech Hepatocyte Growth Factor Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Galaxy Biotech Hepatocyte Growth Factor Product Portfolio
6.8.5 Galaxy Biotech Recent Developments/Updates
6.9 Kringle Pharma
6.9.1 Kringle Pharma Corporation Information
6.9.2 Kringle Pharma Description and Business Overview
6.9.3 Kringle Pharma Hepatocyte Growth Factor Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Kringle Pharma Hepatocyte Growth Factor Product Portfolio
6.9.5 Kringle Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hepatocyte Growth Factor Industry Chain Analysis
7.2 Hepatocyte Growth Factor Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hepatocyte Growth Factor Production Mode & Process
7.4 Hepatocyte Growth Factor Sales and Marketing
7.4.1 Hepatocyte Growth Factor Sales Channels
7.4.2 Hepatocyte Growth Factor Distributors
7.5 Hepatocyte Growth Factor Customers
8 Hepatocyte Growth Factor Market Dynamics
8.1 Hepatocyte Growth Factor Industry Trends
8.2 Hepatocyte Growth Factor Market Drivers
8.3 Hepatocyte Growth Factor Market Challenges
8.4 Hepatocyte Growth Factor Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
